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Introduction
Every year, about 150,000 patients with cancer in the United States develop brain metastasis (BM) (1) , with the lung being the most common primary site for secondary BM (2, 3) .
Survival times after the diagnosis of BM remain poor at only 1.5-9.5 months (4, 5) .
Therefore, prevention of BM is an important consideration for improving survival among patients with cancer. However, to date preventive strategies have met with mixed results, in part because of differences in tumor biology across different types of cancer. For example, radiation therapy has a well-defined role in preventing BM in patients with leukemia or small cell lung cancer, for whom it can improve local control and survival; the role of preventive radiation, if any, in locally advanced non-small cell lung cancer (NSCLC) is unclear. In most trials conducted to date, the use of prophylactic cranial irradiation (PCI) has reduced the cumulative incidence of BM compared with that in control groups, but thus far use of PCI has not affected overall survival (6) (7) (8) (9) . Findings from a recent trial by the Radiation Therapy Oncology Group (RTOG 0214) that PCI decreased the rate of BM but did not improve overall or disease-free survival for patients with stage III disease imply that not all such patients would benefit from PCI and thus it should not be recommended routinely for patients with stage III NSCLC (10) . The ability to predict which patients are at higher risk of developing BM would help in selecting patients for future prospective studies to establish appropriate cancer management strategies to reduce or prevent the occurrence of BM, thus improving the clinical outcome for such patients. (AKT), and mammalian target of rapamycin (mTOR) and participates in the balance of cell survival and apoptosis (19, 20) . The epithelial-to-mesenchymal transition (EMT) is associated with cellular acquisition of motility and invasive properties that promote the formation of metastasis (21). In several cell culture models, EMT is induced by TGF-β or by peptide growth factors via receptor tyrosine kinase signaling (22, 23). In both cases, PI3K is a critical mediator of EMT. This pathway is often activated in many cancers, and uncontrolled PI3K-AKT-mTOR signaling has been linked with poor clinical outcome in patients with lung, bladder, esophageal, or cervical cancer (11, (24) (25) (26) . Moreover, PI3K-AKT-mTOR has been implicated in the regulation of tumor cell invasion in bladder cancer (27) , and the PI3K pathway has been shown to be activated in BMs from breast cancer (28) . To our knowledge, no studies have addressed how genetic variations in PI3K-AKT-mTOR influence the risk of BM in patients with NSCLC. To fill this gap, we sought here to identify potential associations between genetic variations in 5 genes in this pathway-AKT1, AKT2, PIK3CA (catalytic subunit of PI3K), PTEN, and FRAP1 (encoding for mTOR)-with the occurrence of BM in patients with NSCLC. 7 performance score (KPS) of all patients was at least 70, and all had a life expectancy of at least 6 months. Epidemiologic data were collected with a structured questionnaire and included information on demographics, smoking history, alcohol consumption, medical history, family history of cancer, and occupational exposures to potential carcinogens.
Clinical and follow-up data on treatment regimens, disease stage, pretreatment performance status, and vital status at the time of analysis were obtained from the patients' medical records.
Computed tomography (CT) or magnetic resonance imaging (MRI) scans had been obtained from each patient before treatment as part of the disease staging process. All the patients were asked to return to the hospital for examination (which included CT scans of the chest and abdomen) every 2-3 months for the first 2-3 years after completion of treatment and every 6 months thereafter. Repeat brain CT or MRI scans were obtained only in the event of clinical indications, such as neurological symptoms, as the standard of care. BM and survival information was collected from each patient's follow-up records. Of the 363 patients eligible for this study, 46 were excluded, 11 without sufficient DNA for genotyping, 11 with incomplete data on disease staging, and 24 who had died or been lost to follow-up without information on BM, leaving 317 patients with complete information for the current analysis. with follow-up intervals longer than 24 months and those without BM were censored at the date of the last contact. The study was approved by the Ethics Committee of Tongji Medical College. Written informed consent was obtained from all patients before interview.
Polymorphism selection and genotyping
Genomic DNA was isolated from peripheral blood lymphocytes by using the QuickGene Other SNPs previously reported as being associated with survival in NSCLC, or metastasis in general, were also included, such as rs2494732 and rs3803300 (12) . A total of 16 SNPs, including haplotype-tagging SNPs and potential functional SNPs, were selected for genotyping (Table 1) . Among them, 13 SNPs were genotyped by using matrix-assisted laser desorption/ionization-time of flight mass spectrophotometry to detect allele-specific primer extension products with the MassARRAY platform (Sequenom, Inc.). Assay data were analyzed using Sequenom TYPER software (version 4.0). The individual call rate threshold was at least 95%. Three SNPs (rs2494732, rs892119, and rs8100018) were genotyped by TaqMan assay (25) .
Research. 
Statistical analysis
Statistical analyses were done with SPSS software (version 16.0). A Cox proportional hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the influence of genotypes on BM risk. The model was adjusted for sex, age, disease stage, tumor histology, Karnofsky performance status, smoking status, and receipt of chemotherapy or radiotherapy. Kaplan-Meier curves were plotted to assess the cumulative BM probability. Log-rank tests were used to compare the difference between groups. All P values were two-sided, and P values <0.05 were considered statistically significant.
Results

Patient characteristics
Characteristics of the 317 patients (216 men and 101 women) are shown in Table 2 . At a median follow-up interval of 24 months (range, 0-135 months), BM had developed in 99 patients. The sites of metastases included brain only (n=31), bone, lung, adrenals, liver, and other unspecified sites (n= 142), or both (n= 68). Of the 68 patients who had metastases in both brain and other sites, 8 had BM the first site of recurrence, 43 had first recurrence at other sites, and 17 had simultaneous occurrence in more than one site. The median age of all patients was 58 years (range 26-82 years); 55% had stage I-IIIA disease; 68% had adenocarcinoma, and 51% had smoked tobacco (71.7% of men and 5.9% of women). The median time from NSCLC diagnosis to detection of BM was 9 months. Possible associations between patient-and tumor-related characteristics and BM tested by univariate and multivariate analyses (Table 2) 
Effects of single SNPs on risk of BM
We assessed potential associations of each of the 16 individual SNP with BM risk by using a multivariate Cox model. We found that three SNPs, AKT1: rs2498804, AKT1: rs2494732 and PIK3CA: rs2699887, were significantly associated with BM risk. BM rates were higher for patients with the GT/GG genotype of AKT1: rs2498804 (P = 0.012, Figure 1A ), the CT/TT genotype of AKT1: rs2494732 (P = 0.004, Figure 1B ) or the AG/AA genotype of PIK3CA: Figure 1C) . None of the other 13 SNPs analyzed were associated with risk of BM. In general, BM developed more often in patients with the GT/GG genotype of AKT1: rs2498804 (37%), the CT/TT genotype of AKT1: rs2494732 (39%) or the AG/AA genotype of PIK3CA: rs2699887 (44%) than in patients with the TT (23%), CC (24%) or GG genotypes (29%) ( analyses of the other 13 SNPs showed no associations between any other genotype and incidence of BM (Supplementary Tables 1 and 2 ). None of the three genotypes tested was associated with metastasis at sites other than brain (data not shown).
Combined effect of SNPs on risk of BM
For these analyses, we defined the GT/GG genotype of AKT1: rs2498804, CT/TT of AKT1: Table 4 ). This association between genotypes and risk of BM remained significant after patients who had BM at diagnosis were excluded (Table 4) .
Discussion
The PI3K/PTEN/AKT/mTOR pathway is important in balancing cell growth and death. This 
pathway has been shown to be aberrantly activated in several cancer types, including NSCLC (20, 31, 32) . In this study, we determined whether genetic variations in the genes for PI3K, PTEN, AKT1, AKT2, and mTOR were associated with BM risk. We found that SNPs in AKT1: rs2498804, AKT1: rs2494732 or PIK3CA: rs2699887 were associated with BM. To the best of our knowledge, this is the first evidence showing this association in patients with lung cancer.
With validation, this test could be used to predict which patients are at risk for BM, and therefore could be useful for helping to select candidates for trials designed to evaluate preventive interventions.
Two of the polymorphisms associated with BM risk were in AKT1, which consists of 14 exons and is about 26 kb in size. AKT is a central node in cell signaling that regulates several processes, including cell survival, proliferation, and protein synthesis (33) . AKT has been reported to be constitutively activated in NSCLC, enhancing cell survival by blocking induction of apoptosis (31). AKT has been implicated in the regulation of angiogenesis and metastasis, both important processes in cancer development and progression (34, 35) . SNPs and their haplotypes of AKT1 were recently reported to be associated with AKT1 protein expression level and with apoptotic capacity (36) . The protein kinase Akt can induce the EMT and promote enhanced motility in cancer cells in vitro and cellular invasion in vivo (35) .
Expression of pAKT has also been observed in BM from breast cancer (28) . Several studies have linked activated AKT expression to prognosis for patients with lung, bladder, or esophageal cancer (11, 24, 25) . Although the mechanism by which the AKT1 SNPs affect survival remains to be elucidated, it may reflect the fact that these SNPs affect the capacity to eliminate micrometastatic tumor cells via AKT1-mediated apoptosis, thus contributing to survival (37). Collectively, these observations indicate that our finding of an association of SNPs with BM in patients with NSCLC may be biologically plausible.
We also found PIK3CA: rs2699887 polymorphisms to be associated with BM risk.
Patients carrying at least one variant allele in PIK3CA: rs2699887 had nearly twice the risk of BM as those without those variants. PIK3CA is the catalytic domain for PI3K, a known oncogene, and is responsible for initiating signaling through this pathway, activating cell survival signals (38). Overexpression of PIK3CA was demonstrated in primary lung carcinomas and their metastases (39). Genomic amplification of PIK3CA in NSCLC is also common, occurring in 70% of squamous cell carcinomas and 19% of adenocarcinomas (40) .
Increased PI3K activity would result in increased cell survival signals, causing increased metastases. Multiple mechanisms of PI3K activation may be responsible for the high levels of PI3K pathway activation, including PIK3CA mutations (28) . Therefore, the genetic variation tagged by the PIK3CA: rs2699887 SNP would likely cause an increase in PI3K signaling.
Further studies are warranted to validate the association between this polymorphism and BM risk. However, this pathway is complex, and our results suggest that several other genes warrant investigation as well. PI3K/PTEN/AKT/mTOR pathway have a cumulative influence and may further enhance predictive power. However, because the two SNPs identified in this study were tagging SNPs, we are unable to identify the causative SNP and mechanism responsible. Future studies are needed to validate these SNPs in independent patient populations and to perform fine mapping in the vicinity of these gene regions to identify potential causal variants.
Prophylactic radiotherapy has a clearly defined role in the treatment of patients with high-risk acute lymphocytic leukemia. In SCLC, PCI has significantly improved overall survival rates in patients with either limited-stage disease (from 15% to 20% at 3 years) or extensive-stage disease (from 13% to 27% at 1 year) in patients who respond to first-line treatment. Thus, PCI should be considered part of treatment for all patients with extensive SCLC that responds to therapy and for patients with limited-stage SCLC that responds to therapy. Even though the risk of brain failure in NSCLC is not as high as that in SCLC, BM are also quite common in NSCLC, with the incidence ranging from 13% to 54% (1) . Thus, the use of PCI is also being considered for NSCLC. PCI has consistently reduced or delayed the appearance of BM, but none of the studies done to date has ever shown a survival benefit (7, 8, 14) . As noted previously, the recent RTOG 0214 trial of PCI in NSCLC showed that PCI reduced BM rates at 1 year (18% vs. 7.7%, P=0.004), but did not affect overall survival (10) . According to Bovi and White (1), it is unclear whether this lack of survival benefit results from a failure to identify the cohort best suited for preventive therapy, and further implies that not all patients with NSCLC should receive PCI. Moreover, the use of PCI to prevent metastases can have both positive and negative effects (41) . Because no test to date can identify which patients are at high risk of developing BM, PCI has been given unselectively to all patients, which may result in unnecessary toxicity with little potential benefit for some patients. A validated nomogram should be developed to predict the likelihood of BM in patients diagnosed with NSCLC. If the findings from the current study are validated prospectively, in a study with adequate statistical power, these results, in combination with clinicopathologic data, could become the basis for selecting patient subgroups at high risk of BM to receive PCI.
In our study, the incidence of BM was 31% (99 of 317 patients), which is slightly higher than in some studies. Clinicopathologic variables that may portend high risk of BM include adenocarcinomatous histology, high-volume disease, and young age (10) . Most of the patients in our study had adenocarcinoma histology, 45% had advanced disease, and the median age (58 years) was lower than are typical for patients with NSCLC. These differences may explain the relative high incidence of BM in our population, and thus we adjusted for these variables in our multivariate analyses. We further assessed whether the three genotypes were associated with risk of metastasis at other sites, and we found no such association.
These results suggest that metastases in brain and elsewhere may arise through different mechanisms.
In conclusion, this is the first study to evaluate associations between genetic variations in the PI3K-AKT-mTOR pathway and BM risk. We found that 3 SNPs (AKT1: -13-1093 clinical evaluation revealed suggestive findings, such as neurological symptoms. As is true in other studies of risk factors for BM, this could limit the accuracy of a putative molecular marker of BM risk. Independent external patient cohorts are needed to validate our findings.
If validated, these SNPs may prove to be valuable biomarkers for use in combination with clinicopathologic variables to identify patients at high risk of BM who could benefit from PCI.
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